Revance Therapeutics, Inc.

Revance Therapeutics — Jefferies 2017 Global Healthcare Conference

30 slides from Revance Therapeutics's conference presentation, Jun 6, 2017

  1. Slide 1: Jefferies 2017 Global Healthcare Conference

    Slide 1: Jefferies 2017 Global Healthcare Conference

    JEFFERIES 2017 GLOBAL HEALTHCARE CONFERENCE Dan Browne PRESIDENT AND CEO JUNE 2017 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements / Safe Harbor

    Slide 2: Forward-Looking Statements / Safe Harbor

    Forward-Looking Statements / Safe Harbor This presentation contains forward-looking statements, including statements related to: our financial outlook and other financial performance; the process and timing of anticipated future clinical development of our product candidates; our business strategy,

  3. Slide 3: Pre-Commercial Biotechnology Company: Next Generation Neuromodulator

    Slide 3: Pre-Commercial Biotechnology Company: Next Generation Neuromodulator

    PRE-COMMERCIAL BIOTECHNOLOGY COMPANY LONG-DURATION, NEXT GENERATION NEUROMODULATOR REMARKABLE SCIENCE MEDICAL AESTHETICS THERAPEUTICS ADDRESSING $3B+ MARKETS Nerves Muscle

  4. Slide 4: The Vast Potential of Neuromodulators

    Slide 4: The Vast Potential of Neuromodulators

    THERAPEUTICS MEDICAL AESTHETICS Insurance and out-of-pocket pay ... sweaty palms ... migraine ... foot pain ... urinary urge/incontinence ... depression ... heart trouble ... TMJ/teeth grinding Out-of-pocket pay Several currently approved indications ... nasolabial folds ... wrinkles ... marionette

  5. Slide 5: The Challenge of Today's Neuromodulators / Toxins

    Slide 5: The Challenge of Today's Neuromodulators / Toxins

    The Challenge of Today’s Neuromodulators / Toxins Does it work as intended? Could it work BETTER? Higher response rates How long does it last before effect fades? Could it last LONGER? ≥6 months vs. 3 months Are there potential adverse side effects? Could it be SAFER? Even at higher doses EFFICACY S

  6. Slide 6: Our Differentiated Neuromodulator

    Slide 6: Our Differentiated Neuromodulator

    Our Differentiated Neuromodulator One THERAPEUTIC AGENT Patented Peptide Technology DaxibotulinumtoxinA Positively charged peptide that binds with negatively charged area of molecule. NO animal-derived components or human albumin Highly purified, botulinum toxin type A molecule Potential for Better,

  7. Slide 7: Company Highlights

    Slide 7: Company Highlights

    First New Neuromodulator Product in nearly 30 years, demonstrating PROMISING SAFETY, hIGH Response Rates & LONG Duration Preparing to Commercialize in ~$1B* Glabellar Line Market Addressing >$3B Markets in aesthetic & therapeutic applications Multiple near-term catalysts in 2017 Existing funding exp

  8. Slide 8: Our Two-Pronged Path, Aesthetics and Therapeutics

    Slide 8: Our Two-Pronged Path, Aesthetics and Therapeutics

    Our Two-Pronged Path, Aesthetics and Therapeutics BUILD Infrastructure and DRIVE Commercial Excellence Lead Program: Experience in 1,200 patients by end of 2017; file for US marketing approval in 2019 AESTHETICS LEVERAGE Infrastructure and BUILD Therapeutic Portfolio THERAPEUTICS

  9. Slide 9: Progressing in Three Important Indications

    Slide 9: Progressing in Three Important Indications

    Progressing in Three Important Indications INDICATION GLABELLAR LINES CERVICAL DYSTONIA PLANTAR FASCIITIS Demonstrating use in ... SMALL Muscles LARGE Muscles SMOOTH Muscles Stage Phase 3 Phase 2 Phase 2 Potential Differentiation LONG TIME between treatments – Safe and effective SAFE at the high dos

  10. Slide 10: Significant Market Potential in Our Initial Indications

    Slide 10: Significant Market Potential in Our Initial Indications

    Significant Market Potential in Our Initial Indications > $2B Market Opportunity The Strategy: Capture and Build on the Opportunity ...with enhanced neuromodulator Expand indications Grow the Market Target largest segments Take Share 1 GLABELLAR LINES 2 CERVICAL DYSTONIA 3 PLANTAR FASCIITIS NEW pain

  11. Slide 11: 1. Glabellar Lines: Largest Aesthetic Treatment Area

    Slide 11: 1. Glabellar Lines: Largest Aesthetic Treatment Area

    1. Glabellar Lines: Largest Aesthetic Treatment Area Significant Unmet Need for Longer Duration of Effect and Higher Response Rates Versus Currently Available Treatments Current treatments have 3-4 month duration of effect Plan to explore application to other areas of the face UNMET NEED Phase 2 (BE

  12. Slide 12: BELMONT Phase 2 Study: Positive Efficacy and Safety

    Slide 12: BELMONT Phase 2 Study: Positive Efficacy and Safety

    BELMONT Phase 2 Study: Positive Efficacy and Safety Source: IMCA’s 2017 BELMONT Bertucci Short Draft *Vistabel® / Botox® Cosmetics EFFICACY SAFETY Excellent Overall Profile (Mean duration 47 days) Headache Erythema Ptosis (Eyelid Droop) MOST COMMON AEs % with ≥ 1 Point Improvement (IGA-FWS) DESIGN L

  13. Slide 13: BELMONT: 6-Month Duration of Effect Achieved – Patient Example

    Slide 13: BELMONT: 6-Month Duration of Effect Achieved – Patient Example

    SCORES Investigation IGA-FWS 2 0 0 Patient PFWS 2 0 0 BELMONT: 6-Month Duration of Effect Achieved – Patient Example PRE-TREATMENT (Baseline) WEEK 4 6 MONTHS DaxibotulinumtoxinA 40 Units Moderate Wrinkles No Wrinkles No Wrinkles

  14. Slide 14: BELMONT P2 Study: Superior Duration of Response Over BOTOX

    Slide 14: BELMONT P2 Study: Superior Duration of Response Over BOTOX

    BELMONT P2 Study: Superior Duration of Response Over BOTOX® in Every Dose Duration of Response for at Least a 1-point Improvement from Baseline for IGA-FWS Assessment at Maximum Frown (Per-Protocol Population) % of Subjects PLACEBO Weeks RT002 40U RT002 60U RT002 20U BOTOX 20U Median Duration (Weeks

  15. Slide 15: Preparing for U.S. Launch – RT002 Injectable

    Slide 15: Preparing for U.S. Launch – RT002 Injectable

    Preparing for U.S. Launch – RT002 Injectable Glabellar Lines Pivotal Trials Fully Enrolled Randomized, double-blind, placebo-controlled trial at 60+ sites in U.S. and Canada, measuring safety, efficacy, and duration of effect for a single treatment of RT002 600 patients with moderate to severe glabe

  16. Slide 16: BELMONT Data Analyzed Using Phase 3 Endpoints

    Slide 16: BELMONT Data Analyzed Using Phase 3 Endpoints

    BELMONT Data Analyzed Using Phase 3 Endpoints Composite of Subjects with None or Mild and ≥2 Point Change from Baseline on IGA-FWS and PFWS (Week 4) Per-Protocol Analysis Intent-to-Treat Analysis P <.001 BELMONT Data SAKURA Primary Endpoint 4 point scale; Per-protocol population BELMONT Data Percent

  17. Slide 17: 2. Cervical Dystonia: Largest Muscle Movement Disorder

    Slide 17: 2. Cervical Dystonia: Largest Muscle Movement Disorder

    2. Cervical Dystonia: Largest Muscle Movement Disorder UNMET NEED Currently Available Treatments and Therapies Include Oral Medications, Botulinum Toxin Injections, and Surgery Deeper, targeted botulinum toxin delivery is required Significant unmet need for longer duration THE CONDITION Painful/debi

  18. Slide 18: Phase 2 Cervical Dystonia – All Cohorts

    Slide 18: Phase 2 Cervical Dystonia – All Cohorts

    Phase 2 Cervical Dystonia – All Cohorts EFFICACY SAFETY* Most Frequent AEs (week 24) Other Toxins to Treat CD: Dysphagia 13-35% Note: All Subjects with values at both Baseline and Week 4 (n=35). Subjects with a missing value for either Baseline or Week 4 are excluded from the summary. RT002 is an in

  19. Slide 19: Phase 2 Cervical Dystonia: Subject Distribution by Dose

    Slide 19: Phase 2 Cervical Dystonia: Subject Distribution by Dose

    Phase 2 Cervical Dystonia: Subject Distribution by Dose Number of Subjects CD Phase 2 week 24 results, May 2017 Cohort 1 (n=12) Cohort 2 (n=12) Cohort 3 (n=13) LOW Dose Group 100U-240U n=21 HIGH Dose Group 300U-450U n=16 Cohort 1 Cohort 2 Cohort 3

  20. Slide 20: Phase 2 Cervical Dystonia: Overall Response and Duration

    Slide 20: Phase 2 Cervical Dystonia: Overall Response and Duration

    Phase 2 Cervical Dystonia: Overall Response and Duration Duration of Response Overall Response Rate (Week 4; n=35) (In Maintaining ≥ 20% of Treatment Effect Achieved at Week 4*) Percent of Subjects Scores ≥1 Clinical Global Impression of Change (CGIC) Score ≥1 Patient Global Impression of Change (PG

  21. Slide 21: Duration of Response in Cervical Dystonia: RT002 and Dysport

    Slide 21: Duration of Response in Cervical Dystonia: RT002 and Dysport

    Duration of Response in Cervical Dystonia: RT002 and Dysport *Poewe W. et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in CD: a randomized controlled trial. Movement Disorders, 2016. The Dysport trademark is used under license by Galderma Laboratories, L.P. FIG. 2. Mean change fr

  22. Slide 22: 3. Plantar Fasciitis: Highly Prevalent Foot/Heel Disorder

    Slide 22: 3. Plantar Fasciitis: Highly Prevalent Foot/Heel Disorder

    THE CONDITION 3. Plantar Fasciitis: Highly Prevalent Foot/Heel Disorder 1 in 10 People will develop Plantar Fasciitis in their lifetime 2M+ patients in U.S. undergo treatment annually UNMET NEED No Neurotoxin Currently Approved to Treat Plantar Fasciitis Current treatments: NSAIDs, shoe inserts, ste

  23. Slide 23: Readying Our Commercial Infrastructure for Aesthetics Launch

    Slide 23: Readying Our Commercial Infrastructure for Aesthetics Launch

    Specialty sales forces focused on Dermatologists and Plastic Surgeons SALES Targeted effort: brand development, conversion and expansion MARKETING Publication and physician outreach; medical education DEVELOPMENT Unlimited capacity for drug substance; stable product; commercial scale MANUFACTURING O

  24. Slide 24: Proven Team with Deep Experience

    Slide 24: Proven Team with Deep Experience

    Proven Team with Deep Experience Assembling a Commercial Team of Industry Veterans DAN BROWNE Co-Founder, President & CEO >30 years pharmaceutical and medical technology experience Various leadership roles in product development, sales, and marketing ABHAY JOSHI, PH.D., M.B.A. COO >30 years global p

  25. Slide 25: Pipeline in a Product

    Slide 25: Pipeline in a Product

    RT002 INJECTABLE RT001 TOPICAL CERVICAL DYSTONIA PLANTAR FASCIITIS Hyperhidrosis Migraine Shingles & Inflammatory Diseases Neuropsychiatric Disorders Limb Spasticity Migraine Overactive Bladder Musculoskeletal Disorders TMJ/Teeth Grinding Neuropsychiatric Disorders THERAPEUTICS GLABELLAR LINES RT002

  26. Slide 26: Global Commercialization Rights and Expansive IP Coverage

    Slide 26: Global Commercialization Rights and Expansive IP Coverage

    Global Commercialization Right and Expansive IP Coverage COMMERCIALIZATION RIGHTS INTELLECTUAL PROPERTY 183 issued patents with 134 patents applications pending Core US composition and methods patents expire in 2027 and 2029 Potentially extendable for up to 5 years Acquired more than 70 patents/appl

  27. Slide 27: Financial Guidance and Share Overview

    Slide 27: Financial Guidance and Share Overview

    Financial Guidance and Share Overview 1 Cash as of March 31, 2017 and guidance as referenced on May 9th, 2017 2 As of April 27, 2017 CASH AND INVESTMENTS1 $189M FY 2017 GAAP AND NON-GAAP OPEX GUIDANCE1 $108 - $119 GAAP $94 - $102 NON-GAAP (excluding D&A and stock-based compensation) FY 2017 CASH BUR

  28. Slide 28: Key 2017 Milestones

    Slide 28: Key 2017 Milestones

    Key 2017 Milestones AESTHETICS Q1 Q2 Q3 Q4 Glabellar Lines Phase 3 Pivotal Results Q4 2017 THERAPEUTICS Cervical Dystonia Top-line 24-Week Phase 2 Results Completed Plantar Fasciitis Phase 2 Results Q4 2017

  29. Slide 29: Summary

    Slide 29: Summary

    First New Neuromodulator Product in nearly 30 years, demonstrating PROMISING SAFETY, hIGH Response Rates & LONG Duration Preparing to Commercialize in ~$1B* Glabellar Line Market Addressing >$3B Markets in aesthetic & therapeutic applications Multiple near-term catalysts in 2017 Existing funding exp

  30. Slide 30: Jefferies 2017 Global Healthcare Conference

    Slide 30: Jefferies 2017 Global Healthcare Conference

    JEFFERIES 2017 GLOBAL HEALTHCARE CONFERENCE Dan Browne PRESIDENT AND CEO JUNE 2017

Source: SEC EDGAR · 8-K filed Jun 6, 2017

More decks from Revance Therapeutics, Inc.